SureTrader SPDR Advertisement
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, sunspotter
Search This Board:
Last Post: 8/27/2015 10:03:36 PM - Followers: 151 - Board type: Free - Posts Today: 0

RCHA Patent for Treatment of Hodgkin’s Lymphoma
Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma, utility patent application number 61998397, entitled COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF HODGKIN’S LYMPHOMA.
RCHA Recent News
Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia
BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014.  In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases.  Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life.  Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities.  Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:


Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells (WBC) in patients depleted of these elements due to various conditions. 

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs, and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000. Based on this incidence,the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003



Daily View

Weekly View

3 Month Daily View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RCHA News: Current Report Filing (8-k) 06/29/2015 04:29:11 PM
RCHA News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 06/29/2015 11:07:55 AM
RCHA News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 06/29/2015 09:56:25 AM
RCHA News: Securities Registration: Employee Benefit Plan (s-8) 06/18/2015 05:16:57 PM
RCHA News: Current Report Filing (8-k) 06/17/2015 05:08:23 PM
#7384  Sticky Note $RCHA recent news/filings mick 04/17/15 04:23:21 PM
#6618  Sticky Note "in the face of the massive gains we sunspotter 03/17/15 05:07:01 AM
#8119   Will take massive volume to get this ship moving. Revorising 08/27/15 10:03:36 PM
#8118   No buyers, looks like people have woken up valleyview 08/26/15 03:30:38 PM
#8117   I got another email this morning from my ImHereToo 08/26/15 02:25:02 PM
#8116   How about that new email?? Revorising 08/26/15 02:18:56 PM
#8115   Hmmm... News? Information? Does anybody have anything? yamyas 08/26/15 11:43:37 AM
#8114   "What's going on here?" sunspotter 08/26/15 05:00:39 AM
#8113   Quarter 4 my friend. Quarter 4. Revorising 08/25/15 10:17:00 PM
#8112   What's going on here? Nothing? Earache 08/25/15 05:21:13 PM
#8111   I wouldn't you mind sharing the reply you yamyas 08/25/15 10:41:32 AM
#8109   I guess time will tell us soon enough! ImHereToo 08/24/15 07:14:47 PM
#8108   Let's just hope for something good as I Axeman 08/22/15 01:03:23 PM
#8107   Wonder what they have up their sleeve. Revorising 08/20/15 09:46:01 PM
#8106   Depends on the news. I'd guess it jonestint 08/20/15 09:44:28 PM
#8105   How high could this go with decent news? Revorising 08/20/15 09:17:11 PM
#8104   Looked like s lot of selling, but green Revorising 08/20/15 04:38:32 PM
#8103   Why the ouch? jonestint 08/20/15 04:36:53 PM
#8102   Ouch Revorising 08/20/15 01:43:54 PM
#8101   Yes at this point its a lotto ticket...hopefully Revorising 08/19/15 09:00:00 AM
#8100   It's in the process of creating a nice BitCapitals 08/19/15 04:33:24 AM
#8099   New to the pink game? We are .0001 Axeman 08/19/15 03:30:11 AM
#8096   Lets go!!!!!!!! Revorising 08/18/15 02:25:40 PM
#8094   I agree, it's due for a nice run Eltp 08/18/15 10:50:28 AM
#8093   This has a run in the near future. jonestint 08/18/15 10:49:13 AM
#8092   Looks like they are about to put their Eltp 08/18/15 10:29:12 AM
#8091   A 100,000 share buy just bumped the PPS jonestint 08/18/15 10:24:02 AM
#8089   I see the E is gone, just grabbed Eltp 08/18/15 10:08:17 AM
#8088   Any talks about upcoming reveese split? vzheng88 08/17/15 08:33:37 PM
#8085   you are very correct/'Rich Pharmaceuticals Inc. (RCHAE)' mick 08/17/15 04:38:20 PM
#8084   Anyone doing a little research on this Richard Chebaccastocks 08/17/15 02:43:07 PM
#8083   Are you still holding? AssetsBird 08/17/15 04:50:35 AM
#8082   Crooked "management" RCHAE. sunspotter 08/17/15 04:31:39 AM
#8081   BAD MGMT/ rchae mick 08/16/15 05:46:39 PM
#8080   Ok Rich lets go. Drop the E and Revorising 08/16/15 04:58:48 PM
#8079   ***** 10Q will be late******** Revorising 08/14/15 09:55:08 PM
#8078   Thats great at least Ben is trying to Revorising 08/14/15 02:15:15 PM
#8077   Okay well I just looked at a email yamyas 08/14/15 02:13:35 PM
#8076   I looked today but did not see anything new. Revorising 08/14/15 01:49:36 PM
#8075   Anyone get any news on there Financials? yamyas 08/14/15 01:29:02 PM
#8072   I don't believe they stop you from buying ImHereToo 08/14/15 10:01:50 AM
#8070   Why no sticky? This is the only form ImHereToo 08/14/15 09:59:33 AM
#8068   Do some brokers not allow a ticker to Revorising 08/13/15 04:06:33 PM
#8067   MICK, Highlight/ Sticky the #8066 post!!! ImHereToo 08/13/15 03:40:33 PM
#8066   LATEST UPDATE FROM RCHA DIRECT!!! ImHereToo 08/13/15 03:39:39 PM
#8064   MICK, HIGHLIGHT/ STICKY POST # 7993 ImHereToo 08/13/15 01:01:12 PM
#8063   I think once the "E" is off it Bankrupt1 08/13/15 10:56:42 AM
#8062   Sooner or later we will crack .0002. Revorising 08/13/15 10:05:16 AM
#8061   You cannot stickie something that's older than 48 Bankrupt1 08/12/15 08:46:06 AM
#8060   Highlight post 7993 ImHereToo 08/12/15 08:40:43 AM
#8056   Mick please sticky... Revorising 08/11/15 09:45:57 PM
#8055   MODS/ ADMINS, HIGHLIGHT OR STICKY THIS POST ImHereToo 08/11/15 08:23:12 PM